About Us

Delivering Cutting-edge and Essential Insights

Interpace Biosciences® (IDXG) is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer.

Interpace Diagnostics®, LLC is a subsidiary of Interpace Biosciences and is a fully integrated commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. Interpace Diagnostics develops and commercializes molecular diagnostic tests that deliver cutting-edge genetic and mutational analysis that help risk-stratify patient samples for thyroid, pancreatic, lung, and other cancers to better inform treatment decisions.  

Our Mission

Interpace Biosciences works to assist healthcare providers in the diagnosis, triage, and treatment of patients through advanced diagnostics. The molecular diagnostic tests provided by our subsidiary, Interpace Diagnostics, are supported by rigorous science, provide healthcare providers with the ability to avoid unnecessary surgeries and better assess risk of cancer progression in their patients.

Strong Research Collaborations

Interpace Biosciences has established strong research collaborations with key thought leaders in oncology and major cancer centers within the U.S. and abroad. These collaborations enable us to develop and validate proprietary tests in a clinical setting. Interpace Biosciences’ abundant knowledge in oncology and vast testing capabilities allows for these proprietary tests to be tailored to the collaborators’ needs and specifications.


Our molecular diagnostic tests and central laboratory services leverage the latest technology to deliver accurate results.

  • Predicting outcomes years down the road.
  • Determining whether a tumor is truly benign or malignant.
  • Combining Next Generation Sequencing and a miRNA classifier to deliver favorable positive and negative predictive values.
  • Early disease detection.
  • Multiple prognostic platforms to detect & evaluate the most aggressive cancers and diseases.

Our experienced pathologists and Ph.D.’s provide professional support to our customers.

Optimizing Value

We believe that molecular diagnostic testing represents strong patient value given the substantial opportunity it represents to lower healthcare costs by helping to reduce unnecessary surgeries and ensuring the appropriate frequency of ongoing monitoring that requires additional resources. In the era of high deductible and co-insurance plans, patients are taking on more and more responsibility for their own health care costs. Reducing unnecessary surgeries is another way Interpace Diagnostics’ products assist patients. 

Advancing Personalized Medicine

Our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. Interpace Diagnostics currently has five commercialized molecular diagnostic tests in the marketplace: PancraGEN®, ThyGeNEXT®, ThyraMIR®, RespriDX™, and BarreGen®.

State-of-the-art, CLIA-certified Laboratory

All of Interpace Biosciences’ testing services are performed within our clinical reference laboratory located in Pittsburgh, PA, which has Clinical Laboratory Improvement Amendment (CLIA) certification and has been accredited by the College of American Pathologists (CAP).

Meet Our Team

Our success is largely attributed to the efforts of members of our skillful leadership team. As we continue to grow our molecular diagnostics business and develop and/or acquire additional molecular diagnostic tests, we will grow ever more reliant on their skills, experience, and performance.